Pyridines

World Imatinib (CAS 152459-95-5) Market Outlook Report 2020

Retrieved on: 
Wednesday, August 12, 2020

DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Imatinib (CAS 152459-95-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Imatinib (CAS 152459-95-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Imatinib.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Imatinib global market report key points:

DGAP-News: PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2020

Retrieved on: 
Wednesday, August 12, 2020

In the U.S., the FDA (U.S. Food & Drug Administration) granted market approval of BYFAVOTM (remimazolam) for procedural sedation in July 2020.

Key Points: 
  • In the U.S., the FDA (U.S. Food & Drug Administration) granted market approval of BYFAVOTM (remimazolam) for procedural sedation in July 2020.
  • In July 2020, after market approval of BYFAVOTM, PAION, Cosmo and Acacia agreed to assign the BYFAVOTM license agreement signed in 2016 between Cosmo and PAION to Acacia.
  • In Europe, PAION is seeking approval for remimazolam in procedural sedation and in general anesthesia.
  • Procedural sedation: PAION submitted a Marketing Authorization Application (MAA) for procedural sedation to the European Medicines Agency (EMA) in November 2019.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Retrieved on: 
Tuesday, August 11, 2020

SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

Key Points: 
  • SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.
  • The Company anticipates a potential capacity of up to 10 million doses in 2021, depending on titer, yield, and dose amount.
  • In August, the Company will present virtually at EASL The Digital International Liver Congress 2020, which will be held August 2729, 2020.
  • Revenues: Total revenues for the quarter ended June 30, 2020 were $67.0 million, compared to $2.0 million for same period in 2019.

DGAP-News: PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA

Retrieved on: 
Tuesday, August 11, 2020

Aachen (Germany), 11 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that its Chinese remimazolam licensee Yichang Humanwell has recently launched Ruima(R) (remimazolam) in procedural sedation in China.

Key Points: 
  • Aachen (Germany), 11 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that its Chinese remimazolam licensee Yichang Humanwell has recently launched Ruima(R) (remimazolam) in procedural sedation in China.
  • Remimazolam (brand name Ruima(R)) was approved in China for procedural sedation in July 2020.
  • We are delighted by the strong commitment to remimazolam by our Chinese partner Yichang Humanwell.
  • In China, licensee Yichang Humanwell received market approval in procedural sedation in July 2020.

Global Imatinib (CAS 152459-95-5) Market Research Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 10, 2020

The "Imatinib (CAS 152459-95-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Imatinib (CAS 152459-95-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Imatinib.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Imatinib global market report key points:

DGAP-News: PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA

Retrieved on: 
Friday, August 7, 2020

Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with first commercial product sales of Anerem(R) (remimazolam) for the use in general anesthesia in Japan.

Key Points: 
  • Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with first commercial product sales of Anerem(R) (remimazolam) for the use in general anesthesia in Japan.
  • PAION is eligible to royalties between 16-18% in Japan.
  • In Japan, licensee Mundipharma received market approval in general anesthesia in January 2020.
  • The topline data of a Phase III trial in general anesthesia are expected in the second half of 2020.

LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

Retrieved on: 
Wednesday, August 5, 2020

IMPORTANT LORBRENA (lorlatinib) SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION

Key Points: 
  • IMPORTANT LORBRENA (lorlatinib) SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION
    Contraindications: LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity.
  • Depending upon the relative importance of each drug, discontinue LORBRENA or the CYP3A inducer for persistent Grade 2 or higher hepatotoxicity.
  • Overall, 1.5% and 9% of patients required permanent or temporary discontinuation of LORBRENA, respectively, for a CNS effect; 8% required dose reduction.
  • Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter.

RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies

Retrieved on: 
Monday, July 27, 2020

The addition of Talicia to the EnvisionRx national formularies as the unrestricted brand will allow its 3.5 million members nationally to gain access to Talicia.

Key Points: 
  • The addition of Talicia to the EnvisionRx national formularies as the unrestricted brand will allow its 3.5 million members nationally to gain access to Talicia.
  • Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole).
  • In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults.
  • Minimal to zero resistance to rifabutin, a key component of Talicia, was detected in RedHills pivotal Phase 3 study.

Functional Dyspepsia (Non-Ulcer Dyspepsia) Pipeline Monitor, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 24, 2020

The "Functional Dyspepsia (Non Ulcer Dyspepsia) Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Functional Dyspepsia (Non Ulcer Dyspepsia) Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Good progress is anticipated during 2020 and 2021 with Functional Dyspepsia (Non Ulcer Dyspepsia) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials.
  • This Functional Dyspepsia (Non Ulcer Dyspepsia) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Functional Dyspepsia (Non Ulcer Dyspepsia) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Functional Dyspepsia (Non Ulcer Dyspepsia) pipeline.

X-Chem Announces Achievement of Milestone In Orexia Collaboration

Retrieved on: 
Wednesday, July 22, 2020

After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.

Key Points: 
  • After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.
  • Orexia will develop these molecules and is solely responsible for conducting clinical trials with drug candidates derived from licensed compounds, and retains the exclusive global rights to commercialize any resulting products.
  • The licensed compounds further strengthen Orexias promising pipeline of orexin positive modulators, said Mario Alberto Accardi, CEO of Orexia.
  • X-Chem subsequently used DEX screening data and its advanced informatics platform to identify small molecules for Orexia.